Indian drugmakers cashing in on US market as more big-selling drugs gain generic competitors
The approvals of generic Sensipar (cinacalcet) for Indian firms Cipla and Aurobindo Pharma, while providing for the first generic competition for Sensipar, has turned the spotlight on Indian drug majors investing in the development of complex generics, reports The Pharma Letter’s India correspondent.
US biotech major Amgen’s Sensipar brought in $1.72 billion in 2017 sales, or around 7% of the firm's revenue. Indian drugmakers are set to benefit as the US drug regulator works to accelerate the entry of such products to increase competition and lower healthcare costs in the USA.
US FDA Commissioner Dr Scott Gottlieb is also turning the heat on drug prices. Keen to modernize generic drug development and review, the regulator is looking to enable increased competition, promote generic drug substitution and provide affordable options for American patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze